Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696550 · ClinicalTrials.gov registry record · Phase 1
A Safety and PK Study of IV Eravacycline
A Phase 1 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03696550 is a Phase 1 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT03696550, a Phase 1 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection. Male and Female subjects from 8 to \<18 years of age who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Interventions
- DRUG Eravacycline (TP-434)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2021-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03696550
The ClinicalTrials.gov registry entry for NCT03696550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eravacycline (TP-434) is the first listed.
NCT03696550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03696550 about?
NCT03696550 is a clinical study titled "A Safety and PK Study of IV Eravacycline". This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection. Male and Female subjects from 8 to \<18 years of age who fulfill the inclusion/exclusion criteria will be enrolled i...
What is the current status of trial NCT03696550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-12-20. Estimated completion is 2021-03-19.
What interventions are being tested in trial NCT03696550?
The interventions under investigation include: Eravacycline (TP-434) (DRUG).
Who is sponsoring clinical trial NCT03696550?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.